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Analysis of Checkpoint Responses
to Histone Deacetylase Inhibitors
Heather  Beamish,  Robyn Warrener ,  and Br ian G.  Gabr ie l l i
SummarY
Cell c1,cle checkpoints respond to a wide range of stresses to prevent compromise to the
integrity of the cell. The best studied checkpoints are those induced by genotoxic agents that
cause DNA damage. Histone deacetylase inhibitors not only increase the acetylation state of
chromatin histones, but they also perturb the cell cycle, causing both Gl and G2 phase arrests,
the latter bv initiating a checkpoint response. In this chapter we will describe the analysis of the
histone deacetl'lase inhibitor-sensitive G2 checkpoint using synchronized cell populations.
Ke1' \\'ords: Histone deacetylase inhibitor; G2 checkpoint; acetylation; histone; mitosis.
1 .  In t roduc t ion
Cell cl cle checkpoints are mechanisms that respond to a diverse range of
:rre sSe S rhat could ultimately compromise cell integrity. Histone deacetylase
inhibitors (HDACIs) are a class of drugs that block the deacetylat ion of pro-
tc-ins. tlie best characterized being the chromatin histone proteins, although
r.rn increasing number of nonhistone proteins have also been shown to be
rnrrtlified b1' acetylation (1). HDACI treatment of cells often results in pertur-
b;ltions of the cell cycle, notably cell cycle arrests in G1 and G2 phase. The
G I ;.rrre st resultin-e from HDACI treatment can be in part ascribed to tran-
.;ripiirrrral up-regulation of the Cdk2 inhibitor p2lwarrtciPl, a direct result of
lt, rr.r:Ct-l histone acetylation affecting transcription factor accessibility to the
:-: ' ,n-(\r.r  of p21 (2). On the other hand, the mechanism by which HDACI
::- i .1::ncnt inrposes the G2 phase arrest is not clear, but a checkpoint response
,- : :l:.rr.rl rrs opposed to the transcriptional up-regulation of an inhibitor of
r i)K .r-r ir  i tr  (3). Activation of the GZ checkpoint is dependent on the con-
- -: .  i . : i : ()r l  () t  HDACI used (2,4). Many immortal ized and tumor cel l  l ines are
- 'r-.1r,:  ior this checkpoint, but are competent to impose a G2 checkpoint
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arrest in response to other agents, such as DNA-damaging drugs, indicating
that this checkpoint is distinct from other G2 checkpoint mechanisms (.1l). A
consequence of failure of this checkpoint following HDACI treatment is that
cells undergo an aberrant mitosis and often fail cytokinesis, resulting in cells
with tetraploid DNA which have in fact exited mitosis and entered the subse-
quent cell cycle. In this chapter, we wil l outl ine methods for analyzing the
effects of HDACI treatment on the cell cycle, primarily examining tn- CZ
checkpoint response.
2.  Mater ia ls
1. Dulbecco's modified Eagle's medium (DMEM; GIBCO), supplemented with
lj%o (vlv) donor calf serum.
2. Trichostatin A (TSA; Sigma-Aldrich).
3. Sodium butyrate (NaBu; Sigma-Aldrich): 20 mM srock solurion in H,O. make
freshly before addition.
4' Azelaic bishydroxamic acid (ABHA) (generously synthes izedby Mike Wesr, In-
stitute of Molecular Biosciences, University of Queensland), dissolved in DMSO
at a concentration of l0Omg/ml.
5' Thymidine: 100 mM stock solution in PBS. This wil l last for 1 wk ar 4"C. srock
solutions are maintained at -20.C.
6. 2-deoxycytidine: l0 mM stock solution in pBS, store at 4oc for 10 d.
7. Hydroxyurea: 400 mM stock solution in PBS, for long-term storage keep at
-20"c.
8' Propidium iodide (PI): I mg/ml stock solution in H2O, store at 4"Cin the dark to
prevent photo-bleaching.
9' RNase A: l0 mglmL stock solutibn in H2O, store at -20"C. To inactivare any
contaminating DNase present, heat the stock solution to 95"C for l0 min.
10. 4',6-diamidino-2-phenylindole (DAPI): 1 mg/ml stock solurion in H,O. srore ar
4"C in the dark to prevent photo-bleaching.
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Bromodeoxyuridine (Brdu): 5 mM stock solution in H2o, store at 4"c.
Fluorescein isothiocyanate (FITC)-conjugated anti-BrdU monoclonal antibody(Becton Dickson). Keep at 4"C in the dark to prevent photo-bleaching.
Brdu detection buffer: 0.25vo (v/v) Tween-20,2.5 mg/ml BSA, 0.1 mg anri-
BrdU-FITC (Becton Dickson). This buffer should be made when required and be
kept in the dark to prevent breaching of the FlTC-conjugared anrib;dy.
Antibody to mitotic-specific phosphoproreins: MpM-2 antibody (DAKO corpo-
ration, M3514, 0.3 mgiml).
15. Flow cytometer.
16' 3-[4,5-dimethylthiazol-2y1]-2,5-diphenyltetrazolium bromide (MTT; Sigma-
Aldrich).
17. Microplate reader.
18. NETN buffer: 20 mM Tris-HCl (pH7.4), r mM EDTA, r00mM Nacl, 0.57o (vlv)
Nonidet P-40, store at 4bC. Immediately before use add 5 pg/ml of each of
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leupeptin, aprotinin, and pepstatin, 1 mM PMSF (phenylmethylsulfonyl fluoride;
lgd rnM stock in isopropanol; store at -20oC), 10 mM NaF (sodium fluoride'
srock is I M,store at -2}"C),and 0. t mM Na3VOa (sodium orthovanadate; stock is
20 mM, store at -20"C)'
tg. 5X sDS sample buffer: 0.313 M Tris-HCl (pH 6.8), l\Vo (w/v) SDS (sodium
dodecyl sulfate), 50Vo (vlv) glycerol, 0.5 M DTT (dithiothreitol), 0.057o (w/v)
bromoPhenol blue.
ZA. Polyacrylamide gel electrophoresis equipment'
21. Western blot transfer equipment.
22. 0.2,pM PVDF membrane (NEN Life Science Products)'
23. Ponceau S (Sigma).
21. PBS/Tween: 0.05Vo (v/v) Tween-20 in PBS. Store at room temperature'
25. 8lo6o: 5Vo (wlv) dried skimmed milk powder in PBSIfween' Make fresh, store
at 4"C. 
*  
.
26. Protein A-sePharose (Roche).
27 . RC buffer:20 mM Tris-HCl (pH 7.4), 15 mM MgCl2, | {nM DTT, 0.2 rnM ATP,
5 pCi [Trrp] ATP, 15 pg hisrone H1. This buffer contains the radioisotope ^f'p;
therefore. all work with this buffer should be carried out in a suitably designated
area. strict guidelines for exposure, handling, and waste disposal should be out-
lined in the radiation safety plan for the laboratory in question'
28. Acrylamide gel staining buffer: 407o (v/v) meth anol, !\Vo (v/v) acetic acid, 0'5 Vo
1w/v) Comassie blue. Acetic acid is corrosive; aliquot the stock solution in a
fume hood.
29. Acrylamide destaining buffer: 40vo (vlv)methanol, IoTo (vlv) acetic acid. Acetic
acid is corrosive; aliquot the stock solution in a fume hood.
30. Phosphorlmaging system (Molecular Dynamics)'
31. Rehydration brrffe.' 0.17o (v/v) Tween-20 and 37o (w/v) BSA in PBS.
32. Vectorshield (Vector Laboratories).
33. Immunofluorescent microscope.
3. Methods
The methods below outline rhe analysis of the HDACI-initiated GZ check-
point in both synchronized and asynchronously growing cells' Two cell lines
rvill be described: the human cervical cancer cell line, HeLa, an example of a
cell line with a defective HDACl-sensitive G2 checkpoint; and primary cul-
tures of neonatal foreskin fibroblasts (NFF), which have a functional check-
point arrest. Three different HDACIs will be mentioned: sodium butyrate
iNuBu), trichostatin A (TSA), and azelaic bishydroxamic acid (ABHA)'
3.1. Cetl Lines and Culture Conditions
Mycoplasma-free HeLa and NFFs are cultured in complete DMEM (con-
taining l07o lv lvl donor calf serum) at 37'C in the presence of 5Vo COz'
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3.2. Cell Synchrony
Generally, drug treatment experiments are performed on asynchronously
cycling cells, disregarding any cell cycle phase-specific drug effects. However,
in the case of HDACIs, very significant differences are observed, depending on
which phase of the cell cycle the drugs are administered rn (see Xote 1;. the
use of synchronized cells helps to overcome this problem. It also permits more
refined analysis of the cell cycle phase progression, particularly progression
through Gzl}d, than can be obtained using asynchronously growing iultures,
which are normally composed of 60Vo Gl-phase cells.
3.2.1.  HeLa Cel l  Synchrony
HeLa cells are synchronized using a double thymidine block release proto-
col as described below.
1. To block cells in late Gl/early S phase, trypsinize cells and replate at 50Vo
conf luence. Twenty-four hours later,  remove medium and replace with
prewarmed complete DMEM supplemented with 2.5 mM thymidine for 16 h.
2. Release cells from the block with three washes of prewarmed DMEM (without
donor calf serum).
3. Trypsinize and reseed the cells into 1O-cm-diameter dishes at a density of 1 x 106
cells per dish, followed by the addition of prewarmed complete medium supple-
mented with241t"M thymidine and 24 1tM 2-deoxycytidine (see Note 2).
4. After 8 h, block the cells again by the addition of 2.5 mM thymrdine directly inro
the medium. Incubate for a further 16 h.
5. Release the cells from the block with three washes of prewarmed DMEM (with-
out donor calf serum), followed by the addition of prewarmed complete medium
supplemented with 24 1tM thymidine and 24 stM 2-deoxycyridine.
HeLa cells normally enter mitosis witt"rin 10 h after release from the second
thymidine block with 60-80% synchrony using this protocol (see Note 3).
3.2.2. F ibroblast Culture Svnchronv
One to two million NFF cells
then synchronized using a single
in late Gl/earty S phase.
1' Treat exponentially growing NFFs with2 mM hydroxyurea for 24h; the hydrox-
yurea can be added directly into the medium on the plate.
2' Release the cells from the hydroxyurea arrest with three washes of prewarmed
DMEM (without donor calf serum), followed by the addition of prewarmed com-
plete media.
This normally results in up to 50Vo of cells cycling synchronously through S
phase and into mitosis by rz-r4 h after release (see Note 4).
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3.3. HDACI Treatment of Cells
l .  Treat cells with varying concentrations of HDACIs (see Note 5) (see Subhead-
ing 3.11.), either immediately after release from the second thymidine or single
h1'droxyurea block (G1 phase) or within 4-8 h post-release (S-G2 phase).
2. Harvest f-loating and attached treated and untreated cells by trypsinization at vari-
ous times after release.
3. Pellet the cells by centrifugation at 50009 in a microfuge. Wash the cell pellet
ru'ice ri'ith PBS. At this stage, the cell pellet can be divided, and one-third fixed
for FACS analysis (see Subheading 3.4.) and two-thirds set aside for biochemi-
cal analysis (see Subheadings 3.8. and3,f.).
3.4. FIow Cytometric Analysis of the DNA Content of Cells
One-dimensional flow cytometric analysis is used to examine the cell cycle
phase distribution of cell populations. It is particularly useful tn analyzing cell
cycle arrest in synchronized cell populations, where the transit of cells through
cell cycle phases can be followed by analyzing DNA content at successive
tirne points after release from the synchrony arrest.
1. Trear cells (normally 0.5-1 x 106), harvest and pellet as in Subheading 3.3.,
r,'u'ash trvice with PBS, and fix inl}Va ethanol at-20"C. Fixed cells may be stored
for up to 2 wk at -20"C before analysis.
2. Wash fixed cells twice with PBS. Care should be taken when aspirating the PBS,
as the cell pellet is fragile at this stage, and can easily be lost.
3. Stain nuclear DNA with a solution of PI (4 pg/ml-) and RNase A (400 pg/ml-) in
500 pL PBS for 15 min at room temperature in the dark.
.+. Wash the cells three times in PBS, and then filter them through fine silk gauze
(35 prn) to remove cell clumps.
5. Anall 'ze the single cell suspension by flow cytometry, exciting the cells at 488
nm. and measuring the PI intensity through a 600 nm wavelength filter on a
FACScalibur (Becton Dickinson) using CellQuest and ModFit data analysis soft-
\\ 'are. Analyze at least 105 cells for each DNA distribution.
lrlodFit allows the analysis of the diploid and subdiploid populations, the
fornter representing the viable population and the latter the nonviable cells.
\onr iable cells are normally reported as the debris in the ModFit analysis. A
Gl checkpoint arrest wil l be detected as a stable accumulation of cells in a
Gli\ l peak ar a time when the untreated control cells have progressed through
rnitosis inro the subsequent G1 phase. This wil l be apparent as a decrease in the
Gl,/\ l population and an increase in the Gl peak.
3.5. Bromodeoxyuridine (BrdU) Labeling
Thi: nierhod selectively labels S phase cells, allowing their passage through
:'.,rr,.i: to be monitored without he need for drug arrest synchronrzation, avoid-
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ing any potential artifacts caused by synchronization. Cells are pulse-labeled
with the thymidine analog BrdU, which is incorporated into the newly synthe-
sized DNA during S phase. DNA containing BrdU can be identified by using a
fluorescently tagged antibody specifically against BrdU.
1. Pulse-label xponentially growing cells (t x 107) with 10 pM BrdU for 2h.Wash
the cells on the dish twice with pre-warmed PBS to remove the unincorporated
BrdU, followed by addition of prewarmed complete media.
2. Immediately treat the cells with HDACIs for up to 24 h. Harvest all cells both
floating and attached, wash with PBS, and resuspend the cell pellet in 300 pL
PBS. Fix the cells with dropwise addition of 700 1tL I007o ethanol at -20oC to a
final concentrarion of I x 106/100 pL.
3. Following fixation, resuspend the cells in 2 M HCI in 0.57o (v/v) Triton X-100.
Incubate for 30 min at room temperature. Pellet cells gently, by centrifugation at
33009 for 5 min.
4. Neutralize the cells by resuspending the cell pellet in 0.1 Msodium tetraborate
(pH 8.5) for 5 min at room temperature.
5. Detect BrdU incorporation by staining with FlTC-conjugated anti-BrdU mono-
clonal antibody in 400 trtL BrdU detection buffer supplemented with Pl (2 tt"gl
pm) to counterstain the DNA. Incubate in the dark for 30 min at room tempera-
ture.
6. Wash the cells three times with PBS and filter them through fine silk gavze
(35 pm) to produce single-cell suspensions.
7 . Analyze the stained cells by two-dimensional flow cytometry. Excite cells at 488
nm and collect green fluorescence from FITC through a 514 nm filter, indicating
the amount of incorporated BrdU. Measure PI fluorescence though a 600 nm
wavelength filter. Use electronic compensation to prevent contamination of the
PI channel by the FITC fluoresc.ence. Plot FITC fluorescence intensity (FL-1) on
the Y axis and PI staining intensiry (FL-3) on rhe X axis.
In untreated cells, the S phase BrdU-stained population will have progressed
to the GzM peak by 6 hr post-labeling. By 24 h there should be a population of
BrdU-stained cells in the Gl and S phases, representing cells that have under-
gone mitosis (Fig. l, upper panels). If HDACI treatment results in aG2M arrest,
then the BrdU-positive cells (those cells in S phase at the time of treatment) will
remain in the G2Ai4 peak at 24 h, while in the case of a Gl arrest, the BrdU
positive cells will appear only in the G1 peak (Fig. 1, lower panels). These cells
will have been in S phase when treated with HDACI, passed through G2M, and
arrest in the subsequent G1 phase.
3.6. MPM-2 Staining FACS Analysis
To determine the percentage of cells in M phase by FACS analysis, the spe-
cific mitotic phospho-epitope MPM-2 can be used. This will identify rhe pro-
portion of mitotic cells in a Pl-stained GzAr.4 peak.
2 5 1
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Fig. 1. FACS analysis of Brdu staining' 
Fibroblasts were pulse labeled with BrdU
for 2h,then eitherharvestea o, "ttur"J*iitlft"'f' 
rnedium fork or 24h'For the ABHA
treated cel's, HeLa cells (Gl arrest, ,* No,. 12) 
orNFF (G2 arrest) were rabered with
BrdU as above, u.ra,n"nireated *i,t iOO Fg/mL 
AIHA for24h' The mask shows the
positions of the G1, s, and G2lrv' phase 
gr"Ju-tuu"tJ popularions. Cells not labeled
'w1th grdu would appear below the dotted line'
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l .Treatei therexponent ia l lygrowingcel lsorsynchronizedcel lswithHDAClsand
22 l?1""":ii:il1ii:t';ffi::i;""',ff?#lT wash with 
pBs and incubate with anti-
M P M - 2 a n t i b o d y d i l u t e d U 2 0 0 i n P B s f o r l h a t 4 o C . W a s h c e l l s t w i c e w i t h
pBS and incubare with speci"r-r;;;ific FIr!^rabeled 
secondary antibody and
PI (2 pg/ml) io 
"ou,.,."r-stain 
.t,i pNe, for 30 min at 4oC in the dark.
3. wash ."tt' t*i." with 
pBS una .ounterstain the DNA with PI 
(2 velmD for 30
min at 4oC in the dark. Filter th;;;lit through 
a fine silk gauze-j'.:.f)
4. Analyze MpM-2-positive ."il";ring 
fiuuiiut" flow cytometry with cell Quest
and Modfit softw;re (Becton Dickinson)'
M i t o t i c c e l l s h a v e a 4 N D N A c o n t e n t b y P l s t a i n i n g a n d a r e p o s i t i v e f o r
MPM-2sta in ing 'whereasG2-phasece l lshavea4NDNAcontentbyPls ta in -
ing and no MPM-2 staining'
3.7. MTT Cell Proliferation AssaY
\1TT(3-[4'5-dirnethylthiazol-2yl]-2'5-diphenyltetrazoliumbromide)mea-
sures .rirochonoJu u.tinity, which'is 
a good *urk"t of cell viability and m a-
sures Prol i ferat ion'
l .Seedce l l s in tog6-we l lp la tesa tadens i t yo f2_5x103perwe l l ,24hpr to r to the
a.ldition of HDACIs'
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2' on day 0 (the day HDACIs are added) and for the follow ing 3-4d, measure rhecell viability and proliferation in untreated control and HDACI-treated cells. AddMTT to the culture media at a final concentration of 0.5 mg/ml and incubate rheplates fbr 4 h at 37"C.
3' Precipitate the insoluble formazan product by centrifugation of the plate, fol-
. lowed by aspiration of the supernatant (see Note 6).4' Dissolve the formazan crystals in 100 pL DMSo with gentle shaking at roomtemperature' This routinely takes 5 min, but if a large u*ount of formazan crys-tals form, then a longer time is required to dissolve all the crystals.5' Measure absorbanc e at 570 nm using a microplate reader.
3.8. Immunoblotting for Acetylated Histones
As a measure of inhibition of histone deacetylases, the level of histone acety-lation can be determined by immunoblotting, using either a generic anti-acetyllysine antibody or acetylation site-specific antibodies.
1' Pellet and lyse synchroni zed' and treated celrs in 500 pL of NETN buffer on icefor 30 min.
Determine the protein levels using bicinchoninic acid according to the manu-facturer's instructions (BCA; Pierce chemical co.) using bovine serum albumin(BSA) as a srandard.
To 20 pg of prorein lysate dilured to 20 pL in NETN, add 5 pL 5X SDS samprebuffer and boil for 5 min.
4' Resolve samples on a 12.57o SDS-PAGE, and transfer to a pvDF membraneusing semi-dry western blotting equipment according to manufacturer,s instruc-tions' Assess sample loading uy uiiei Ponceau S (Sigma) sraining of the mem-branes' The histone proteins stain as prominent bands between l5 and 25 kDa.
ffiT;tJ.t 
Ponceau s staining by washing membrane rhree rimes for 5 min in pBS/
5' Block the membrane in Blotto for I hlt Detect acetylated histone levels witheither generic or acetylation site-specific antibodies, and the appropriate horse-radish-peroxidase-conjugated secondary antibody using enhanced chemilumi-nescenr (ECL; NEN) derecrion.
This method analyzes the whole cell lysate, including the chromatin his-tones which are not extracted using normal detergent and low-salt buffers. withthe generic anti-acetyl lysine antibodies, other acetylated nonhistone proteinsare also detected' Fig.2 shows acetylation of o-tubulin in response to ABHAand TSA, but not NaBu treatment.
3.9. Immunoprecipitation and Cyclin B/Cdc2 Kinase Assay
cyclin Blcdc} is activated at the G2lMtransition. Its activity is essential forentry into mitosis, and the inactivation and destruction of cyclin B is requiredfor exit from mitosis (5). Thus' measurement of the activity of cyclin BlCdcZ
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+wrra*. , g-tubulin
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Fig.2. Whole-cell lysates of HeLa cells treated for 24 h with either lO mM sodium
butyrate (NaBu), 100 ng/ml TSA, or 100 pg/ml ABHA. Lysates were resolved by
12.570 SDS-PAGE, transferred to PVDF membrane, immunoblotted with an anti-
acetyl lysine antibody (cell Signalling Ac-K-103), and then developed with enhanced
chemiluminescence staining. The blot shorqs acetylated histone H3 and H4 and acety-
lated cr-tubulin (see Note 13).
and the abundance of the cyclin B protein by immunoblotting are excellent
indicators of entry into and exit from mitosis. The measurement of cyclin B/
Cdc1 activity is particularly useful when used in conjunction with synchro-
ntzed cell culturir, u, it provides a biochemical measure of transit through
mitosis. Cyclin BlCdc} aitivity is determined by the immunoprecipitation of
the complex followed by an in vitro kinase assay performed on histone Hl,
which is its in vivo substrate. Flow cytometry can provide only an indirect
measure of GZM transition, and may be inaccurate, especially if a high pro-
portion of cells fail cytokinesis. The latter may result in cells with 4N DNA
content, which will be detected rn a G2lM peak, although these cells are actu-
ally in G1 phase. The failure of cytokinesis is common in HDACI treated cells'
1. Resuspend and lyse treated cells (1-5 x 106) on ice for 30 min in 1 mL NETN
buffer supplemented with 0.15 M NaCl.
2. Remove cellular debris by centrifugation at 16,0009 for 10 min at 4oC'
3. Derermine the protein concentration of the lysates (see Subheading 3.8.) trans-
fer 1 mg to a fresh microfuge tube'
4. Incubate the precleared cell lysate (see Note 7) with anti-cyclin B antibody (0.5 pg)
prebound to :O trtL 50Vo suspension of protein A-sepharose (Roche) (see Note 8),
ior 3 h at 4oC with constant mixing. Wash precipitates three times with NETN,
once with 20 mM Tris-HCl (pH7 '4), I nM DTT'
5. In an approved area for radioactive work, resuspend the precipitates in 30pL RC
buffer. Incubare ar 30oC for 15 min. Add 10 pL 5X SDS sample buffer and boil
for 5 min. Run samples on a l\Vo PAG, stain with acrylamide staining buffer for
30 min with rocking, and destain with acrylamide destain buffer to determine the
even loading of histone H1'
6. euantitate histone phosphorylation using a Phosphorlmaging system (Molecular
Dynamics).
Ll-
in
, le
*
)r
d
2
254 Beamish, Warrener, and Gabrieili
7 ' In addition to the immunoprecipitation of the cycrin B complex and kinase assayas performed previously, a 20pg sample of each lysate should be prepared forimmuno-blotting' Add 5x SDS iampie buffer ro rhe lysare and boil (see sub-heading 3.8.). These samples can be kept at -2}.Cfor 2 wk before running on aPAG to determine the levels of cell cycte regulatory proteins cyclin B I and cdc2.The level of cyclin B 1 should increase u, ,.11, enter mitosis, and decline on exit.The level of Cdc2 remains constant through the cell cycle and acts as a conve-nient loading control.
3.1 0. I mmunofluorescent Staining
one of most dramatic consequences of a defect in the HDAcl-sensitive G2checkpoint is the appearance of cells undergoing an aberrant mitosis followingHDACI treatment (see Note 9). To examine this phenotype, immunostaining
of fixed cells is performed.
1' seed exponentially growing cells onto coverslips (see Note 10). To obtain ahigher proportion of cells undergoing mitosis, these cells can be synchronized asdescribed in Subheading 3.2.
2' Treat cells with HDACI, and harvest the cells on the coverslips at various timesafter treatment' wash cells with PBS, fix with -20"c ll}vomethanol, and storeat-20oC in methanol until required. The optimal time for harvesting the synchro-nized cultures is when the control and HDACI-treated samples both display ahigh proportion of the rounded mitotic phenotype, which normally occurs g-12 hafter synchrony release. with asynchronou, 
"ultures, a high proportion of mi-totic cells are evident 16-24 h after drug treatment.
3' Air-dry coverslips, and rehydrate with a drof of rehydration buffer for I h arroom temperature.
4' stain the cells with anti-cr-tubulin (1:10Q0 in rehydration buffer; Amersham), fort h at room temperature in a humidified chambe r (see Note 1r).5' Wash coverslips three times for 15 min with PBs containing o.Tvodried skimmedmilk powder, then incubate with an appropriate fluorochrome-conjugated sec-ondary antibody and DAPI (5 pglml-), io rtuin the DNA, for 20min in rhe dark ina humidified chamber.
6' Wash coverslips three times with PBS containing 0.lvodried skimmed milk pow-der' once with PBS, and then mount by inverting onto a glass slide on a drop ofvectorshierd mounting solution to preserve the fruorescence.7 ' Store coverslips in the dark at 4'c, or analyzeimmediately with a immunofluo-rescence microscope' Determine the numblr of aberrant mitotic cells with eachtreatment (see Note 9).
3'l I. Determining the Effective Dose of HDACI
We have used a range of different HDAcIs to examine the cell cycle effectsof these drugs' In each case, it is important to define the concentration of drugrequired to produce aGZM effect-either G2 arrest in cells with an intact
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Fig. 3. Titration of ABHA with DG75 Burkitts lymphoma cells.- Asynchronously
growing cells were treated with the indicated concentrations of ABHA for 24 h and
then harvested. A portion of each sample was fixed for FACS analysis of the DNA
content (A), and the remainder was lysed and immunoblotted with anti-acetyl lysine
antibody (B). The levels of acetylated histone H3 and H4, and acetylated tubulin are
shown.
HDAcl-sensitive checkpoint or aberrant mitosis in cells defective for this
checkpoint control. For example, a low dose of ABHA, which produces only a
relatively small increase in histone acetylation in DG75 Burkitts lymphoma
cells, produces a very strong accumulation of these cells in G1 phase and loss
of the S phase population. In contrast, at higher doses, which produce substan-
tial histone acetylation, the accumulation of these cells inG2lM is more promi-
nenr (Fig. 3). To examine the effective dose of HDACI, the following protocol
should be used.
1. Treat asynchronous cell cultures with a range of doses of HDACI (see Note 5).
2. Harvest at 4,8, and 24 h after treatment. Determine histone and nonhistone pro-
tein acetylation by immunoblotting (see Subheading 3.8.).
3. In addition, determine the effect on the cell cycle by analyzing cells harvested at
24 hby flow cytometry (see Subheading 3.4.).
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At low doses of HDACIs, a Gl arrest is often observed without any GZ|M
effects. This is in part a consequence of the transcriptional up-regulation of the
CDK inhibitor p}lwAiltclr Q). Higher doses are required to observe GzlM
effects.
4. Notes
l. When 100 pglml- ABHA is added to cells in the S phase, a large proportion of
the cells will undergo an aberrant mitosis, and subsequently within 24h a large
proportion are dead. If the same amount of ABHA is added to cells in the S phase
of the cell cycle and removed in the G2 phase, then cell death does not occur. In
addition, 100 pg/ml ABHA added in G2 phase does not produce an aberrant
mitosis and causes little cell death (6). Similar results have been observed for
additional HDACIs tested.
Thymidine depletes the deoxycytidine triphosphate pool, and in this way induces
a Gl block in the cell cycle. The inhibitory action of thymidine is alleviated by
removal of the high concentration of thymidine and the addition of 2-deocyti-
dine to the medium, which appears to be the rate limiting factor.
HeLa cells are the best characterized cell line for use with a double block release
protocol. Many cell lines will not successfully exit the second arrest, or if they
do, they will have a reduced level of synchrony. For most cell lines, an over-
night block with 2 mM hydroxurea produces a robust G1/S arrest that is readily
reversed upon removal of the drug, resulting in populations which progress into
mitosis with 50Vo synchrony. Synchrony with all these procedures is improved
if the tissue-culture hood or room in which the release is performed is also
prewarmed to 37"C.
Primary fibroblast cultures are difficult to synchronize, and after release a vari-
able proportion of the population often remains arrested in Gl. This does not
provide any difficulties in interpreting data, as it is effectively a noncycling
population that remains constant throughout the experiment. A higher degree of
synchrony can be obtained with NFF if they are first synchronized by serum
starvation with 0.57o serum for 48 h, then stimulated to enter the cell cycle with
107o serum readdition, then blocked with2 mM hydroxyurea for 24 h, and then
released from this arrest by removal of the drug as described. The drawback
with this method is that the proportion of noncycling cells is often higher than
after the single hydroxyurea block.
All HDACIs examined appear to have similar effects on the cell cycle. Stability
is a problem for both TSA, with a half-life of 8 h, and NaBu. In addition, NaBu
has a number of additional effects on the cell; therefore other HDACIs are used
in preference. Typical concentration ranges for HDACIs used on Hela and NFF
cells are shown in Table 1.
To aspirate the supernatant from the plate, a multi-channel pipet is used to remove
approx 90Vo of the total volume in each well.
7. Preclearing a lysate.removes all proteins present which will bind nonspecifically
to the protein A or'b sepharose used to purify the antibody of interest. This is
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Table 1
Typical Concentration Ranges for HDACIs Used on Heta and NFF Cells
ABHA
TSA
NaB
SBHA (Suberohydroxamic Acid)
Oxamflatin
Depsipeptide
10-200 pg/ml
100-500 ng/ml
10-20 mM
50-200 pg/ml
5-20tr:.M
0.5-2.01t"M
done by first incubating the lysate with 30 pL of protein A/G-sepharose for 30
min with rocking at 4"C. The protelF ,A./G is removed by centrifugation of the
lysate at 80009 for 1 min in a microfuge, and transfer the supernatant to a fresh
microfuge tube for the subsequent immunoprecipitation.
8. To prebind the antibody to the protein A-sepharose, take 0.5 pg anti-cyclin B
antibody and mix it with 30 pL 50Vo protein A-sepharose. Incubate with rocking
for 20 min at 4oC, pellet the complex by centrifugation at 5000g in a microfuge,
wash with an equal volume of PBS, and remove the supernatant. Repeat he wash-
ing step three times.
The decision to use protein A or protein G to pull down the antibody of
interest will depend on the species of animal in which the antibody was raised
and which subclass of immunoglobulin it is. Protein A binds well to antibodies
raised in humans, pigs, rabbits, guinea pigs, and mice, while protein G binds
antibodies generated in humans, horses, cows, pigs, sheep, goats, rabbits, ham-
sters, guinea pigs, rats, and mice.
Protein A/G-sepharose is typically stored rn 2A7o ethanol; the ethanol will
need to be removed before addition into a cellular lysate. This is done by wash-
ing the protein A/G-sepharose five times in a large volume of PBS. The washed
protein A/G-sepharose can be stored at 4"C for 10 d.
9. Aberrant mitosis refers to a mitotic cell which is abnormal in appearance (Fig. 4
and ref.6). Normally, chromosomes congress to the metaphase plate, with a very
distinctive spindle cap on either side of the midline. HDACI-treated mitotic cells
contained well-formed spindles, but DNA staining shows chromosomes failing to
migrate to the midline of the cell. Staining of the kinetochores can also be carried
out to demonstrate the failure of the chromosomes to migrate to the midline.
10. Owing to the variation in quality of coverslips, all coverslips are precleaned
before use, to ensure that cells will adhere to them. Coverslips (10 mm) are first
boiled in water for 20 min, then rinsed in l00%o ethanol, and allowed to air dry.
When dry, they are packaged into tubes and autoclaved before use.
i 1. As the volumes involved in the immunofluorescent staining of coverslips are
low, a humidified chamber is used. This should be a dark box with a lid. Line the
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Fig. 4. Aberrant mitosis phenotype. Cells attempting mitosis in the presence of
ABHA undergo aberrant mitosis. HeLa cells synchronized by a double thymidine
block and then released and treated without (upper panels) or with 100 pg/ml ABHA
(lower panels), cells were fixed as the cultures entered mitosis. Cells were stained for
DNA and microtubules. The normal congression of condensed chromosomes at
metaphase is clearly observed with the DNA staining. The ABHA-treated mitotic
cells contained well formed spindles, but DNA staining shows chromosomes failing
to migrate to the midline of the cell-
. ' i '
bottom of the box with blotring paper, and wet it with PBS. Take a length of para-
film large enough to place all the coverslips on, and place on the blotting paper'
Mark the parafilm with the identification of each coverslip, to prevent a mix-up
of the samples. Use this chamber for the rehydration and the incubations with the
primary und r".o.rdary antibodies. Place the coverslips cell-side down on a drop
of tn. buffer/solution in question for each step. For washing, transfer the cover-
slips to aZ4-well plate cell-side up.
In NFF cells, a G2M checkpoint is activated in the presence of the HDACI'
ABHA. In HeLa cells this checkpoint is not activated, and the cells progress
through the cell cycle into G1 phase. In the figure of the BrdU-Hela cells, there
afe a significant froportion of cells still in the G2M or 4N peak after 24 h of
treatment. This peak corresponds to cells which have gone through mitosis but
have failed cytokinesis; therefore, they are in fact Gl-phase cells.
Differential acetylation of the H3 and H4 histone can be seen when cells are
treated with different HDACIs. At present it is unclear whether this is a result of
the inhibitors having differential effects, or whether it is a result of the relative
instability of TSA and NaBu'Eompared to ABHA.
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